Omeprazolo Git (Omeprazole)

Omeprazole, the active ingredient in Omeprazolo Git, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults and children. GNH USA supplies Omeprazolo Git as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related conditions. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with the condition.

Adverse reactions to omeprazole are generally mild to moderate and vary with duration of therapy.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hepatotoxicity: elevated liver enzymes indicating liver stress. - Hypomagnesemia: low magnesium levels with prolonged use. - Fracture risk: increased incidence of hip, wrist or spine fractures with long‑term therapy.

When prescribing omeprazole, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe kidney impairment. - Review concomitant medications: evaluate for potential drug‑drug interactions. - Monitor long‑term use: consider periodic assessment of magnesium and bone health. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Elderly patients: start with the lowest effective dose and monitor response. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atorvastatin: increased plasma concentration, raising risk of myopathy. - Methotrexate: higher systemic exposure, potentially causing toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring more frequent monitoring. - Digoxin: modest increase in serum levels, may need dose adjustment. - Diazepam: enhanced sedation, monitor for excessive CNS depression.